- Home
- CRGX vs FFWM Comparison
CRGX vs FFWM Comparison
Compare CRGX & FFWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- FFWM
- Stock Information
- Founded
- CRGX 2021
- FFWM 1990
- Country
- CRGX United States
- FFWM United States
- Employees
- CRGX N/A
- FFWM N/A
- Industry
- CRGX
- FFWM Major Banks
- Sector
- CRGX
- FFWM Finance
- Exchange
- CRGX Nasdaq
- FFWM Nasdaq
- Market Cap
- CRGX 190.0M
- FFWM 378.0M
- IPO Year
- CRGX 2023
- FFWM 2014
- Fundamental
- Price
- CRGX $4.61
- FFWM $5.21
- Analyst Decision
- CRGX Hold
- FFWM Buy
- Analyst Count
- CRGX 7
- FFWM 4
- Target Price
- CRGX $5.33
- FFWM $7.25
- AVG Volume (30 Days)
- CRGX 2.0M
- FFWM 768.6K
- Earning Date
- CRGX 08-11-2025
- FFWM 07-31-2025
- Dividend Yield
- CRGX N/A
- FFWM N/A
- EPS Growth
- CRGX N/A
- FFWM N/A
- EPS
- CRGX N/A
- FFWM N/A
- Revenue
- CRGX N/A
- FFWM $113,564,000.00
- Revenue This Year
- CRGX $57.81
- FFWM $182.35
- Revenue Next Year
- CRGX N/A
- FFWM $7.79
- P/E Ratio
- CRGX N/A
- FFWM N/A
- Revenue Growth
- CRGX N/A
- FFWM N/A
- 52 Week Low
- CRGX $3.00
- FFWM $4.42
- 52 Week High
- CRGX $25.45
- FFWM $8.52
- Technical
- Relative Strength Index (RSI)
- CRGX 61.57
- FFWM 45.17
- Support Level
- CRGX $4.32
- FFWM $5.04
- Resistance Level
- CRGX $4.63
- FFWM $5.63
- Average True Range (ATR)
- CRGX 0.15
- FFWM 0.19
- MACD
- CRGX 0.04
- FFWM -0.00
- Stochastic Oscillator
- CRGX 76.44
- FFWM 29.17
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.